Twelve prostate biopsies detect significant cancer volumes (> 0.5 mL)

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Prostate cancer diagnosis relies heavily on biopsy accuracy.
• Traditional sextant biopsy may miss clinically significant tumours.
• Evaluating extended biopsy protocols is crucial for improved detection.

Purpose of the Study:

• To compare prostate cancer detection rates and pathological features between 12-core and traditional sextant biopsies.
• To assess the impact of additional biopsy cores on cancer volume, Gleason score, and pathological stage.

Main Methods:

• Retrospective analysis of 27 patients undergoing radical prostatectomy for prostate cancer.
• Comparison of prostatectomy specimens from cancers detected via sextant biopsy versus an extended 12-core biopsy protocol.
• Analysis included cancer volume, Gleason score, Mostofi grade, and pathological stage.

Main Results:

• The 12-core biopsy detected cancer in 29% of cases that would have been missed by sextant biopsy.
• No significant difference was observed in mean Gleason score (6.1) or Mostofi grade between the two methods.
• A significant difference in mean tumour volume was found (5.7 mL for sextant vs. 1.99 mL for 12-core; P=0.0138).

Conclusions:

• Extended 12-core prostate biopsy protocols enhance the detection of prostate cancer.
• While tumour volume detection differs, core biopsy number does not significantly alter Gleason score or final pathological stage.
• Additional biopsy cores improve cancer detection without compromising established grading and staging parameters.